A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Phase 2 Active not recruiting 48 enrolled University of Colorado, Denver ALX Oncology Inc. · collab Academic GI Cancer Consortium (AGICC) · collab Criterium, Inc. · collab Eli Lilly and Company · collab Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer

Timeline

Start: 2022-07-28
Primary completion: 2025-12-01
Completion: 2026-03-01

Publications

Lentz RW, Lang J, Pitts TM, Blatchford P, Hu J, Jordan KR, Van Bokhoven A, Bagby SM, Dominguez ATA, Binns CA, Robinson HR, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Lieu CH, Wadlow RC, Spencer K, Scott AJ, Boland PM, Hochster HS, Messersmith WA. Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer. Cancer Res Commun. 2025 Nov 1;5(11):2039-2052. doi: 10.1158/2767-9764.CRC-25-0332.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous
Subject	Evorpacept	Protein / enzyme biologic	15 mg/kg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications